Clinical Trials Details

NRG-GI004/S1610 COMMIT (Colon)

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Objective

This clinical trial was temporarily closed to accrual on June 4, 2020.

Clinical Trial Categories

  • Cancers and Other Neoplasms